|Awarded On||February 18, 2015|
|Title||Leukemia inhibitory factor receptor signaling and function in cancer|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Li Ma|
|Cancer Sites||Breast, Gallbladder, Liver and Intrahepatic Bile Duct|
Deregulation of signaling pathways that control organ size, such as the AKT-TOR and Hippo-YAP pathways, can lead to tumorigenesis and metastasis. A major barrier in eradicating the death and suffering from breast cancer is the shortage of clinically proven prognostic markers and therapeutic agents for metastasis. Although many breast cancer metastasis-promoting genes have been reported, they have not been translated into clinical benefits except HER2. On the other hand, few genes have been established as metastasis suppressors. Using a high-throughput sequencing approach, our laboratory identified leukemia inhibitory factory receptor (LIFR) as a novel breast cancer metastasis suppressor down...